Acute coronary syndromes: Diagnosis and management, part I

Mayo Clinic Proceedings

Volumn 84, Issue 10, 2009, Pages 917-938

  Kumar, Amit ^a   Cannon, Christopher P ^b,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Thrombolysis in Myocardial Infarction Study Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CAPTOPRIL; CLOPIDOGREL; DALTEPARIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; EPLERENONE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; GLYCERYL TRINITRATE; HEPARIN; HIRULOG; MORPHINE; NADROPARIN; NIFEDIPINE; NITRIC ACID DERIVATIVE; PLACEBO; PRASUGREL; PRAVASTATIN; RANOLAZINE; TICAGRELOR; VALSARTAN; VERAPAMIL;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONSERVATIVE TREATMENT; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG CONTRAINDICATION; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; HEART INFARCTION; HUMAN; INFLAMMATION; LABORATORY TEST; MONOTHERAPY; NECROSIS; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PHYSICIAN; REVASCULARIZATION; RISK ASSESSMENT; THORAX PAIN; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 70350225564     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.10.917     Document Type: Conference Paper

References (152)

1. Lloyd-Jones D, Adams R, Carnethon M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2009 update. a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published correction appears in Circulation. 2009;119(3):e182]. Circulation. 2009 Jan 27;119(3):480-486. Epub 2008 Dec 15.
2. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation. 1988;77(6):1213-1220. (Pubitemid 18141118)
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992;326(5):310-318.
4. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104(3):365-372. (Pubitemid 32666962)
5. Corti R, Fuster V, Badimon JJ, Hutter R, Fayad ZA. New understanding of atherosclerosis (clinically and experimentally) with evolving MRI technology in vivo. Ann N Y Acad Sci. 2001;947:181-195. (Pubitemid 34059913)
6. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol. 2001;12(4):383-389. (Pubitemid 32675498)
7. Webster MWI, Chesebro JH, Smith HC, et al. Myocardial infarction and coronary artery occlusion: a prospective 5-year angiographic study. J Am Coll Cardiol. 1990;15:218A.
8. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20(5):1262-1275. (Pubitemid 30262927)
9. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994;90(2):775-778. (Pubitemid 24242744)
10. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89(1):36-44.
11. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993;69(5):377-381. (Pubitemid 23171108)
12. Sukhova GK, Schönbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999;99(19):2503-2509. (Pubitemid 29228279)
13. Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 2001;104(16):1899-1904. (Pubitemid 32983231)
14. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation. 2000;101(6):598-603. (Pubitemid 30094729)
15. von Birgelen C, Klinkhart W, Mintz GS, et al. Plaque distribution and vascular remodeling of ruptured and nonruptured coronary plaques in the same vessel: an intravascular ultrasound study in vivo. J Am Coll Cardiol. 2001;37(1):1864-1870. (Pubitemid 32499972)
16. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med. 2001;134:224-238. (Pubitemid 32113325)
17. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990;82(3)(suppl):II38-II46.
18. Lendon CL, Davies MJ, Born GV, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis. 1991;87(1):87-90.
19. Tanaka A, Shimada K, Sano T, et al. Multiple plaque rupture and Creactive protein in acute myocardial infarction. J Am Coll Cardiol. 2005 May 17;45(10):1594-1599. Epub 2005 Apr 25. (Pubitemid 40704491)
20. Sano T, Tanaka A, Namba M, et al. C-reactive protein and lesion morphology in patients with acute myocardial infarction. Circulation. 2003 Jul 22;108(3):282-285. Epub 2003 Jun 30. (Pubitemid 36899017)
21. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation. 2003;108(14):1664-1672. (Pubitemid 37243650)
22. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation. 2003;108(15):1772-1778. (Pubitemid 37296082)
23. Lüscher TF, Tanner FC, Noll G. Lipids and endothelial function: effects of lipid-lowering and other therapeutic interventions. Curr Opin Lipidol. 1996;7(4):234-240. (Pubitemid 26280233)
24. Chen L, Chester MR, Crook R, Kaski JC. Differential progression of complex culprit stenoses in patients with stable and unstable angina pectoris. J Am Coll Cardiol. 1996;28(3):597-603. (Pubitemid 26288639)
25. Moreno PR, Bernardi VH, López-Cuéllar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina: implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation. 1996;94(12):3090-3097. (Pubitemid 26427472)
26. Fosang AJ, Smith PJ. Human genetics: to clot or not. Nature. 2001;413: 475-476.
27. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334(17):1090-1094. (Pubitemid 26120186)
28. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation. 2002;106(7):804-808. (Pubitemid 34266604)
29. Conti CR, Brawley RK, Griffith LS, et al. Unstable angina pectoris: morbidity and mortality in 57 consecutive patients evaluated angiographically. Am J Cardiol. 1973;32(6):745-750.
30. Mizuno K, Satumo K, Miyamoto A, et al. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes. N Engl J Med. 1992;326(5):287-291.
31. The TIMI IIIA Investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit lesion in patients presenting with ischemic cardiac pain at rest: results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation. 1993;87(1):38-52.
32. Sullivan E, Kearney M, Isner JM, Topol EJ, Losorda DW. Pathology of unstable angina: analysis of biopsies obtained by directional coronary atherectomy. J Thromb Thrombolysis. 1994;1(1):63-71.
33. Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med. 1986;315(15):913-919. (Pubitemid 16023677)
34. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303(16):897-902. (Pubitemid 10021186)
35. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med. 1983;309(7):396-403.
36. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat unstable angina. N Engl J Med. 1988;319(17):1105-1111. (Pubitemid 18254337)
37. Cohen M, Demers C, Gurfinkel EP, et al.; Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337(7):447-452.
38. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published corrections appear in N Engl J Med. 2001;345(23):1716 and 2001;345(20):1506]. N Engl J Med. 2001;345(7):494-502.
39. Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction [published correction appears in N Engl J Med. 1998;339(6):415]. N Engl J Med. 1998;338(21):1488-1497.
40. Cannon CP, Weintraub WS, Demopoulos LA, et al. TACTICS-Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344(25):1879-1887.
41. Cannon CP, Braunwald E. Time to reperfusion: the critical modulator in thrombolysis and primary angioplasty. J Thromb Thrombolysis. 1996;3(2): 117-125. (Pubitemid 26237534)
42. Anderson JL, Adams CD, Antman EM, et al.; Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2007;50(7):e1-e157.
43. McDermott MM, Mandapat AL, Moates A, et al. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. Arch Intern Med. 2003;163(18):2157-2162. (Pubitemid 37248780)
44. Pope JH, Ruthazer R, Beshansky JR, Griffith JL, Selker HR. Clinical features of emergency department patients presenting with symptoms suggestive of acute cardiac ischemia: a multicenter study. J Thromb Thrombolysis. 1998;6(1):63-74. (Pubitemid 28429942)
45. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, US Public Health Service, US Dept of Health and Human Services, 1994. AHCPR Publication No. 94-0602 (124).
46. Abidov A, Rozanski A, Hachamovitch R, et al. Prognostic significance of dyspnea in patients referred for cardiac stress testing. N Engl J Med. 2005;353(18):1889-1898. (Pubitemid 41565954)
47. Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med. 1993;118(2):81-90. (Pubitemid 23013622)
48. Morise AP, Haddad WJ, Beckner D. Development and validation of a clinical score to estimate the probability of coronary artery disease in men and women presenting with suspected coronary disease. Am J Med. 1997;102(4):350-356. (Pubitemid 27249101)
49. Jayes RL Jr, Beshansky JR, D'Agostino RB, Selker HP. Do patients' coronary risk factor reports predict acute cardiac ischemia in the emergency department? A multicenter study. J Clin Epidemiol. 1992;45(6):621-626.
50. Cannon CP, McCabe CH, Stone PH, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. J Am Coll Cardiol. 1997;30(1):133-140.
51. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA. 1999; 281(8):707-713. (Pubitemid 29113451)
52. Hyde TA, French JK, Wong CK, Straznicky IT, Whitlock RM, White HD. Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression. Am J Cardiol. 1999;84(4):379-385.
53. Yusuf S, Pearson M, Sterry H, et al. The entry ECG in the early diagnosis and prognostic stratification of patients with suspected acute myocardial infarction. Eur Heart J. 1984;5(9):690-696. (Pubitemid 14006300)
54. Brush JE Jr, Brand DA, Acampora D, Chalmer B, Wackers FJ. Use of the initial electrocardiogram to predict in-hospital complications of acute myocardial infarction. N Engl J Med. 1985;312(18):1137-1141. (Pubitemid 15008028)
55. Braunwald E, Jones RH, Mark DB, et al. Diagnosing and managing unstable angina. Circulation. 1994;90(1):613-622.
56. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28(5):1328-1428. (Pubitemid 26377013)
57. McCord J, Nowak RM, McCullough PA, et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation. 2001;104(13):1483-1488. (Pubitemid 32917339)
58. Shapiro BP, Babuin L, Jaffe AS. Cardiac biomarkers. In: Murphy JG, Lloyd MA, eds. Mayo Clinic Cardiology: Concise Textbook. 3rd ed. Rochester, MN: Mayo Clinic Scientific Press and New York: Informa Healthcare USA; 2007:773-780.
59. Jaber WA, Prior DL, Marso SP, Houghtaling PL, Menon V, Harrington RA. CHF on presentation is associated with markedly worse outcomes among patients with acute coronary syndromes: PURSUIT trial findings. Circulation. 1999;100(suppl I):I433.
60. Steinhubl SR, Berger PB, Mann JT III, et al. CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [published correction appears in JAMA. 2003;289(8):987]. JAMA. 2002;288(19):2411-2420.
61. Batter A. The Euro Heart Survey of Acute Coronary Syndromes (EHS-ACS) Presented at: European Society of Cardiology Scientific Sessions. Stockholm, Sweden; Sept 1-5, 2001.
62. Hamm CW, Heeschen C, Goldmann B, et al. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels [published correction appears in N Engl J Med. 1999;341(7):548]. N Engl J Med. 1999;340(21):1623-1629.
63. Heeschen C, Hamm CW, Goldmann B. PRISM Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 1999;354(9192):1757-1762.
64. FRagmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354(9180):708-715.
65. Boersma E, Pieper KS, Steyerberg EW, et al. PURSUIT Investigators. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. Circulation. 2000;101(22):2557-2567. (Pubitemid 30350632)
66. Théroux P, Alexander J Jr, Pharand C, et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation. 2000;102(20):2466-2472. (Pubitemid 30839535)
67. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001;104(23):2767-2771. (Pubitemid 33126648)
68. Cotter G, Cannon CP, McCabe CH, Charlesworth A, Caspi A, Braunwald E. Prior peripheral vascular disease and cerebrovascular disease are independent predictors of increased 1 year mortality in patients with acute coronary syndromes: results from OPUS-TIMI 16 [abstract]. J Am Coll Cardiol. 2000;35(suppl A):410A.
69. Santopinto J, Gurfinkel EP, Torres V, et al. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. Am Heart J. 2001;141(4):566-572. (Pubitemid 32260722)
70. Mauri F, Franzosi MG, Maggioni AP, Santoro E, Santoro L. Clinical value of 12-lead electrocardiography to predict the long-term prognosis of GISSI-1 patients. J Am Coll Cardiol. 2002;39(10):1594-1600. (Pubitemid 34494281)
71. Morrow DA, Cannon CP, Rifai N, et al.; TACTICS-TIMI 18 Investigators. Ability of minor elevations of troponin I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001;286(19):2405-2412. (Pubitemid 33098158)
72. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335(18):1342-1349. (Pubitemid 26360452)
73. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol. 1998;31(7):1460-1465. (Pubitemid 28273285)
74. Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E; OPUS-TIMI 16 Investigators. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. Am J Cardiol. 2001;87(5):636-639, A10.
75. Sabatine MS, Morrow DA, Cannon CP, et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 substudy. J Am Coll Cardiol. 2002;40(10):1761-1768.
76. Baldus S, Heeschen C, Meinertz T, et al. CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003 Sep 23;108(12):1440-1445. Epub 2003 Sep 2. (Pubitemid 36176799)
77. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;108(3):275-281. Epub 2003 Jul 7. (Pubitemid 36899016)
78. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345(14):1014-1021. (Pubitemid 34940793)
79. Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004;44(2):335-339. (Pubitemid 38950592)
80. Arakawa N, Nakamura M, Aoki H, Hiramori K. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology. 1994;85(5):334-340. (Pubitemid 24337744)
81. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105(15):1760-1763.
82. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835-842. (Pubitemid 30643610)
83. Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes: application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J. 2002;23(3): 223-229. (Pubitemid 36358244)
84. James SK, Lindbäck J, Tilly J, et al. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol. 2006;48(6):1146-1154. Epub 2006 Aug 28. (Pubitemid 44345147)
85. Eagle KA, Lim MJ, Dabbous OH, et al. GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291(22):2727-2733. (Pubitemid 38725422)
86. Granger CB, Goldberg RJ, Dabbous O, et al; Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19): 2345-2353.
87. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031-2037. (Pubitemid 30786479)
88. Wiviott SD, Morrow DA, Frederick PD, et al. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;44(4):783-789.
89. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13.
90. de Winter RJ, Windhausen F, Cornel JH, et al; Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. 2005;353(11):1095-1104.
91. Hirsch A, Windhausen F, Tijssen JG, Verheugt FW, Cornel JH, de Winter RJ; Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) investigators. Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. Lancet. 2007;369(9564):827-835.
92. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006 Oct 3;48(7):1319-1325. Epub 2006 Sep 12.
93. O'Donoghue M, Boden WE, Braunwald E, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008;300(1):71-80. (Pubitemid 351920406)
94. Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360(21): 2165-2175.
95. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease [published correction appears in J Am Coll Cardiol. 1999;34(6):1850]. J Am Coll Cardiol. 1999;33(1):273-282.
96. Meine TJ, Roe MT, Chen AY, et al; CRUSADE Investigators. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005; 149(6):1043-1049. (Pubitemid 40848149)
97. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006 Jun 27;113:2906-2913. Epub 2006 Jun 19. (Pubitemid 44297231)
98. Gibson CM, Pride YB, Aylward PE, et al. Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. J Thromb Thrombolysis. 2009 Jan;27(1):11-17. Epub 2008 Aug 10.
99. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1622-1632.
100. Gottlieb SO, Weisfeldt ML, Ouyang P, et al. Effect of the addition of propranolol to therapy with nifedepine for unstable angina: a randomized, double-blind, placebo-controlled trial. Circulation. 1986;73(2):331-337. (Pubitemid 16127411)
101. The Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J. 1986;56(5):400-413.
102. Théroux P, Taeymans Y, Morissette D, Bosch X, Pelletier GB, Waters DD. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol. 1985;5(3):717-722. (Pubitemid 15141983)
103. Rizik D, Timmis GC, Grines CL, Bakalyar D, Schreiber T. Immediate use of beta blockers, but not calcium blockers, improves prognosis in unstable angina [abstract]. Circulation. 1991;84(suppl. II):II-345.
104. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319(7):385-392.
105. The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J. 1984;5(7):516-528.
106. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol. 1998;21(9):633-641. (Pubitemid 28420407)
107. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q wave myocardial infarction: results of a double-blind, randomized, multicenter trial. N Engl J Med. 1986;315(7):423-429.
108. Wilcox RG, Hampton JR, Banks DC, et al. Trial of early nifedepine in acute myocardial infarction: the Trent study. Br Med J (Clin Res Ed). 1986;293(6556):1204-1208. (Pubitemid 17180155)
109. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217-2225. (Pubitemid 39473159)
110. Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428.
111. ISIS-4 Collaborative Group. ISIS-4: randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345(8951):669-685.
112. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet. 1995;345(8951): 686-687.
113. Pfeffer MA, McMurray JJ, Velazquez EJ, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both published correction appears in N Engl J Med. 2004;350(2):203]. N Engl J Med. 2003 Nov 13;349(20):1893-1906. Epub 2003 Nov 10.
114. Gustafsson I, Torp-Pedersen C, Køber L, Gustafsson F, Hildebrandt P; Trace Study Group. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. J Am Coll Cardiol. 1999; 34(1):83-89.
115. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published corrections appear in N Engl J Med. 2000;342(18):1376 and 2000;342(10):748]. N Engl J Med. 2000;342: 145-153.
116. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med. 2003 Apr 3;348(22):2271]. N Engl J Med. 2003;348(14):1309-1321. Epub 2003 Mar 31.
117. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E; MERLIN-TIMI 36 Investigators. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J. 2006;151(6):1186.e1-1186.e9. (Pubitemid 43866616)
118. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al.; MERLIN-TIMI 36 Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN- TIMI 36 randomized trial. JAMA. 2007;297(16):1775-1783. (Pubitemid 46658646)
119. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina; results of a Canadian multicenter trial. N Engl J Med. 1985;313(22):1369-1375. (Pubitemid 16211835)
120. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336(8719):827-830.
121. CURE Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000;21(24):2033-2041.
122. Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527-533.
123. Sabatine MS, Cannon CP, Gibson CM, et al; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005 Sep 14;294(10):1224-1232. Epub 2005 Sep 4.
124. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervent ion). J Am Coll Cardiol. 2006;47(1):216-235.http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db= PubMed&list-uids=16386696&dopt=Abstract.
125. King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2008 Jan 15;117(6):e161]. Circulation. 2008;117(2):261-295. Epub 2007 Dec 13.
126. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery) [published correction appears in Circulation. 2005;111(15):2014]. Circulation. 2004;110(9):1168-1176.
127. Wiviott SD, Trenk D, Frelinger AL, et al; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007 Dec 18;116(25):2923-2932. Epub 2007 Dec 3. (Pubitemid 350291199)
128. Wiviott SD, Braunwald E, McCabe CH, et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001-2015. Epub 2007 Nov 4.
129. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. [epub before print.]. N Engl J Med. 2009;361.
130. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials [published correction appears in Lancet. 2002;359(9323):2120]. Lancet. 2002;359(9302):189-198. (Pubitemid 34113814)
131. Klootwijk P, Meij S, Melkert R, Lenderink T, Simoons ML. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). Circulation. 1998;98(14):1358-1364. (Pubitemid 28462794)
132. Alexander JH, Harrington RA, Tuttle RH, et al. PURSUIT Investigators. Prior aspirin use predicts worse outcomes in patients with non-ST- elevation acute coronary syndromes. Am J Cardiol. 1999;83(8):1147-1151.
133. Kastrati A, Mehilli J, Neumann FJ, et al. Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006 Apr;295(13):1531-1538. Epub 2006 Mar 13.
134. Giugliano RP, White JA, Bode C, et al.; EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009 May 21;360:2176-2190. Epub 2009 Mar 30.
135. Théroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 1993;88(5, pt 1):2045-2048. (Pubitemid 23326081)
136. Rich JD, Maraganore JM, Young E, et al. Heparin resistance in acute coronary syndromes. J Thromb Thrombolysis. 2007 Apr;23(2):93-100. Epub 2007 Jan 13. (Pubitemid 46416853)
137. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135(7):502-506.
138. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335.
139. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable Angina/Non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100(15):1602-1608. (Pubitemid 29477268)
140. Ferguson JJ, Califf RM, Antman EM, et al; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292(1):45-54.
141. de Lemos JA, Blazing MA, Wiviott SD, et al. A to Z Investigators. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. Eur Heart J. 2004;25(19):1688-1694.
142. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100(15):1593-1601.
143. de Lemos JA, Rifai N, Morrow DA, et al. Elevated baseline myoglobin is associated with increased mortality in acute coronary syndromes, even among patients with normal baseline troponin I: a TIMI 11B substudy. Circulation. 1999;100(suppl I):I372-I373.
144. Stone GW, McLaurin BT, Cox DA, et al. ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21):2203- 2216.
145. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006 Apr 6;354(14):1464-1476. Epub 2006 Mar 14.
146. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol. 2001;37(2): 475-484.
147. van Es RF, Jonker JJC, Verheugt FWA, Deckers JW, Grobbee DE. Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis- 2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360(9327):109-113.
148. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347(13):969-974.
149. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines [published correction appears in Circulation. 2004;110(6):763]. Circulation. 2004;110(2):227-239.
150. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357.
151. Cannon CP, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [published correction appears in N Engl J Med. 2006;354(7):778]. N Engl J Med. 2004 Apr 8;350(15):1495-1504. Epub 2004 Mar 8.
152. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22. (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20-28.